Drug intelligence / Profile preview

siPTENP1

Development stage
Preclinical
Modality
Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intratumoral, Intravenous
01

Overview

siPTENP1 is a small interfering RNA (siRNA) designed to silence the expression of the long non-coding RNA (lncRNA) PTENP1, which is a pseudogene of the PTEN tumor suppressor. PTENP1 normally acts as a competing endogenous RNA (ceRNA) by sequestering microRNAs (such as miR-20a) that would otherwise target PTEN mRNA for degradation. By knocking down PTENP1, siPTENP1 reduces the available "sponge" for these microRNAs, leading to decreased PTEN protein levels and subsequent activation of the PI3K/Akt signaling pathway. This activation promotes oncogenic processes including cell proliferation, migration, invasion, and resistance to chemotherapy (e.g., adriamycin) in various malignancies, most notably breast cancer. siPTENP1 is primarily utilized as a research tool to elucidate the functional significance of the PTENP1/PTEN axis in cancer progression.

Other names
siRNA-PTENP1siRNA-PTENP-1siRNA-PTENP 1PTENP1 siRNAPTENP-1 siRNAPTENP 1 siRNAsmall interfering RNA targeting PTENP1
02

Targets

PTENP1 (Phosphatase and tensin homolog pseudogene 1 RNA transcripts)

Beyond the preview

Go deeper on siPTENP1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on siPTENP1.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call